The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study

Miyata, Ryo; Hamaji, Masatsugu; Omasa, Mitsugu; Miyahara, So; Aoyama, Akihiro; Takahashi, Yutaka; Sumitomo, Ryota; Huang, Cheng-long; Hijiya, Kyoko; Nakagawa, Tatsuo; Yokoyama, Yuka; Kawakami, Kenzo; Sonobe, Makoto; Ikeda, Masaki; Fujinaga, Takuji; Suga, Michiharu; Hirota, Shinya; Kojima, Fumio; Bando, Toru; Takahashi, Mamoru; Terada, Yasuji; Tanaka, Shōji; Katakura, Hiromichi; Muranishi, Yusuke; Miyahara, Ryoji; Date, Hiroshi

doi:10.1007/s00595-020-02102-7

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, radiation therapy was avoided for similar reasons. As the results of previous studies analyzing therapeutic approaches for the treatment of recurrences of thymoma have been controversial (16,17), further studies are warranted to establish which modalities among chemotherapy, surgical treatment, or radiotherapy, are appropriate for the treatment of recurrent thymoma.…”

Section: Discussionmentioning

confidence: 99%

Acute myeloid leukemia post‑cytotoxic therapy following chemotherapy for thymoma: A case report

Manabe,

Tani,

Inano

et al. 2024

Med Int

View full text Add to dashboard Cite

The present study reports the case of a patient with acute myeloid leukemia post-cytotoxic therapy (AML-pCT) that developed following chemotherapy for thymoma. A 64-year-old female patient underwent surgical resection for a mediastinal tumor and was diagnosed with stage IVa thymoma. She received chemotherapy, including carboplatin/etoposide, carboplatin/paclitaxel and amrubicin monotherapy. At 56 months following surgery, she developed blastosis and was diagnosed with AML-pCT. As demonstrated herein, although treatment for thymoma is associated with a markedly lower frequency of myeloid neoplasms post-cytotoxic therapy (MN-pCT) than treatment for other malignancies, such as breast carcinoma, it is important to be aware that MN-pCT may occur as a late complication of thymoma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute myeloid leukemia post‑cytotoxic therapy following chemotherapy for thymoma: A case report

Manabe,

Tani,

Inano

et al. 2024

Med Int

View full text Add to dashboard Cite

show abstract

“…Применение лучевой терапии также остается спорным у пациентов с распространенной стадией НЭО тимуса, по данным R. Miyata и соавт., данное вмешательство, наоборот, ассоциировалось с худшим прогнозом [21].…”

Section: Discussionunclassified

Neuroendocrine tumor of thymus with ectopic production of adrenocorticotropic hormone in a 13-year-old child. Case report, 5-year follow-up

Slashchuk,

Reinberg,

Bazarova

et al. 2024

J. Mod. Onco.

View full text Add to dashboard Cite

Neuroendocrine tumors (NET) of the thymus are rare, usually aggressive, and prone to metastatic lesion. Ectopic adrenocorticotropic hormone (ACTH) secretion in thymic NET (TNEN) is associated with poor prognosis. Most of TNET express somatostatin receptors, it allows the use of somatostatin receptor scintigraphy (SRS) and SPECT/CT or PET/CT with 68Ga-labeled peptides for diagnosis and staging of the disease. Surgery (macroscopic-complete resection) is the mainstay treatment for TNET. Now, there are no unequivocal data in adjuvant therapy and its effectiveness. We present a case report of the pediatric patient with well differentiated atypical ACTH-producing thymic carcinoid. This localization was verified by whole body somatostatin receptor scintigraphy with 111In-DTPA-octreotide (Octreoscan). The patient proceeded with the surgical treatment followed by remission of hypercorticism without adjuvant chemotherapy. Tumor recurrence with redevelopment of ACTH-ectopic syndrome was detected after 67 months of observation.

show abstract

“…In patients with ATC, systemic chemotherapy is the standard of care, but the disease is so rare that an optimal regimen has not yet been established. Based on the results of small phase II trials and retrospective studies, combination chemotherapy, platinum-based doublets (e.g., carboplatin and paclitaxel [ 6 , 10 ], cisplatin or carboplatin and etoposide for thymic neuroendocrine carcinoma [ 11 , 12 , 13 ]), and other multidrug regimens (e.g., doxorubicin, cisplatin, vincristine, and cyclophosphamide [ADOC] [ 14 , 15 ] and cisplatin, doxorubicin, and vincristine [CAP] [ 16 ]) are selected for patients with ATC in clinical practice. The efficacy of these regimens are modest; however, the response to chemotherapy and outcomes vary considerably among patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

Mimori

Shukuya

et al. 2022

Cancers

View full text Add to dashboard Cite

The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology.

show abstract

The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study

Cited by 4 publications

References 28 publications

Acute myeloid leukemia post‑cytotoxic therapy following chemotherapy for thymoma: A case report

Acute myeloid leukemia post‑cytotoxic therapy following chemotherapy for thymoma: A case report

Neuroendocrine tumor of thymus with ectopic production of adrenocorticotropic hormone in a 13-year-old child. Case report, 5-year follow-up

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study

Contact Info

Product

Resources

About